Biomarkers of interferon beta therapy in multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 34, Issue 8, 2014, Pages 600-604

  Graber, Jerome J ^a   Dhib Jalbut, Suhayl ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 7; TISSUE INHIBITOR OF METALLOPROTEINASE; VERY LATE ACTIVATION ANTIGEN 4; PHARMACOLOGICAL BIOMARKER;

B LYMPHOCYTE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; DISABILITY; DISABILITY SEVERITY; DISEASE ACTIVITY; HUMAN; LYMPHOCYTE ACTIVATION; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REVIEW; ANIMAL; BLOOD; DECISION MAKING; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; DECISION MAKING; HUMANS; IMMUNOTHERAPY; INTERFERON-BETA; MULTIPLE SCLEROSIS; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84905367120     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0144     Document Type: Review

References (44)

1. Aung LL, Brooks A, Greenberg SA, Rosenberg ML, Dhib-Jalbut S, Balashov KE. 2012. Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells. J Neuroimmunol 250(1-2):99-105.
2. Axtell RC, de Jong BA, Boniface K, ven der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. 2010. T helper type 1 and 17 cells determine efficacy of interferon-b in multiple sclerosis and experimental encephalomyelitis. Nat Med 16(4):406-412.
3. Bartosik-Psujek H, Stelmasiak Z. 2006. The interleukin-10 levels as potential indicator of positive response to interferon beta treatment of multiple sclerosis patients. Clin Neurol Neurosurg 108(7):644-647.
4. Bushnell SE, Zhao Z, Stebbins C, Cadavid D, Buko AM, Whalley ET, Davis JA, Versage EM, Richert JR, Axtell RC, Steinman L, Medori R. 2012. Serum IL-17F does not predict poor response to IM IFNb-1a in relapsing-remitting MS. Neurology 79(6):531-537.
5. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernandez O, Brassat D, Comabella M, Wang J, Barcellos LF, Baranzini SE, Oksenberg JR. 2008. Genome-wide pharamacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 65(3):337-344.
6. Cadavid D, Kim S, Peng B, Skurnick J, Younes M, Hill J, Wolansky LJ, Cook SD. 2011. Clinical consequences of MRI activity in treated multiple sclerosis. Mult Scler J 17(9):1113-1121.
7. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, Frank JA, McFarland HF. 1997. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 41(5):669-674.
8. Chiarini M, Serana F, Zanotti C, Capra R, Rasia S, Rottoli M, Rovaris M, Caputo D, Cavaletti G, Frigo M, Frigeni B, Clerici R, Rezzonico M, Caimi L, Imberti L. 2012. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. Mult Scler J 18(6):788-798.
9. Comabella M, Craig DW, Morcillo-Suarez C, Rio J, Navarro A, Fernandez M, Fernández M, Martin R, Montalban X. 2009a. Genome-wide scan of 500, 000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 66(8):972-978.
10. Comabella M, Lunemann JD, Rio J, Sanchez A, Lopez C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. 2009b. A type 1 interferon signature in monocytes is as sociated with poor response to interferon-beta in multiple sclerosis. Brain 132(12):3353-3365.
11. Cosentino M, Zaffaroni M, Tojano M, Giorrelli M, Pica C, Rasnini E, Bombelli R, Ferrari M, Ghezzi A, Comi G, Livrea P, Lecchini S, Marino F. 2012. Dopaminergic modulation of CD4 + CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-b therapy. Neuroimmu-nomodulation 19(5):283-292.
12. Dhib-Jalbut S, Sumandeep S, Valenzuela R, Ito K, Patel P, Rametta M. 2013. Immune response during interferon-beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study. J Neuroimmunol 254(1-2):131-140.
13. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Rivoiro C, Ferrero C, Picco E, Ripellino P, Giuliani G, Montanari E, Clerico M; Italian Multiple Sclerosis Study Group. 2008. MRI activity and neutralizing antibody as predictors of response to interferon-b treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 79(6):646-651.
14. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F. 2009. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 65(5):499-509.
15. Francis GS, Rice GP, Alsop JC; PRISM Study Group. 2005. Interferon-b-1a in MS: results following development of neutralizing antibodies in PRISM. Neurology 65(1):48-55.
16. Graber JJ, Dhib-Jalbut S. 2009. Protective autoimmunity in neurologic disease. Pharmacol Ther 121(2):147-159.
17. Graber JJ, Dhib-Jalbut S. 2011. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci 305(1-2):1-10.
18. Graber JJ, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut S. 2007. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol 185(1-2):168-174.
19. Graber JJ, Zhan M, Ford D, Kursch F, Francis G, Panitch H, Bever C, Calabresi PA, Dhib-Jalbut S. 2005. Interferon-beta induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neu-roimmunol 161(1-2):169-176.
20. Hallal-Longo DE, Mirandola SR, Oliveira EC, Farias AS, Pereira FG, Metze IL, Brandão CO, Ruocco HH, Damasceno BP, Santos LM. 2007. Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-beta. J Interferon Cytokine Res 27(10):865-873.
21. Hartung H-P, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, et al. 2013. Interleukin 17F level and interferon beta response in patients with multiple sclerosis. JAMA Neurol 70(8):1017-1021.
22. Hesse D, Krakauer M, Lund H, Søndergaard HB, Langkilde A, Ryder LP, Sorensen PS, Sellebjerg F. 2010. Breakthrough disease during interferon-b therapy in MS: no signs of impaired biologic response. Neurology 74(18):1455-1462.
23. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. 2004. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol 152(1-2): 126-139.
24. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S; European Interferon Beta-1a IM Dose-Comparison Study Investigators. 2005. Neutralizing antibodies and efficacy of interferon b1a: a 4-year controlled study. Neurology 65(1):40-47.
25. Killestein J, Polman CH. 2011. Determinants of interferon b efficacy in patients with multiple sclerosis. Nat Rev Neurol 7(4):221-228.
26. Lee L-F, Axtell R, Tu GH, Logronio K, Dilley J, Yu J, Rickert M, Han B, Evering W, Walker MG, Shi J, de Jong BA, Killestein J, Polman CH, Steinman L, Lin JC. 2011. IL-7 promotes Th1 development and serum IL-7 predicts clinical response to interferon-beta in multiple sclerosis. Sci Transl Med 3(93):93ra68.
27. Leonard WJ, O'Shea JJ. 1998. JAKS and STATS: Biological implications. Annu Rev Immunol 16:293-322.
28. Malhotra S, Bustamente MF, Perez-Miralles F, Rio J, de Villa MC, Vegas E, Nonell L, Deisenhammer F, Fissolo N, Nurt-dinov RN, Montalban X, Comabella M. 2011. Search for specific biomarkers of IFNb bioactivity in patients with multiple sclerosis. PLoS One 6(8):e23634.
29. McGraw CA, Lublin FD. 2013. Interferon beta and glatiramer acetate therapy. Neurotherapeutics 10(1):2-18.
30. Panitch HS, Hirsch RL, Haley AS, Johnson KP. 1987. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1(8538):893-895.
31. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Mar-askovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, Meyer JD, Davison BL. 1994. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 180(5):1955-1960.
32. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. 2010. Recommendations for clinical use of data on neutralizing antibodies to interferon-b therapy in multiple sclerosis. Lancet Neurol 9(7):740-750.
33. Rudick R, Ransahoff R, Lee J, Peppler R, Yu M, Mathisen PM, Tuohy VK. 1998. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50(5):1294-1300.
34. Rudick RA, Lee J-C, Simon J, Ransohoff RM, Fisher E. 2004. Defining interferon b response status in multiple sclerosis patients. Ann Neurol 56(4):548-555.
35. Rudick RA, Rani MR, Xu Y, Lee J-C, Na J, Shrock J, Josyula A, Fisher E, Ransahoff RM. 2011. Excessive biologic response to IFNb is associated with poor treatment response in patients with multiple sclerosis. PLoS One 6(5):e19262.
36. Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G, Houvenagel E, Berthelot JM, Pagnoux C, Dernis E, Melac-Ducamp S, Bouvard B, Asquier C, Martin A, Puechal X, Mariette X, Club Rhumatismes et Inflammation Section of the SFR. 2013. Pattern of demyelinating occurring during anti-TNF-a therapy: a French national survey. Rheumatology 52(5):868-874.
37. Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Ro-cak S, De Stefano N. 2011. Combined MRI lesions and relapses as surrogate marker for disability in multiple sclerosis. Neurology 77(18):1684-1690.
38. Sturzebacher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, Frank JA, Staudt L, Martin R, McFarland HF. 2003. Expression profiling identifies re-sponder and non-responder phenotypes to interferon-b in multiple sclerosis. Brain 126(6):1419-1429.
39. Uitedehaag BM, Barkhof F, Coyle PK, Gardner JD, Jeffery DR, Mikol DD. 2011. The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin 27(8):1529-1537.
40. Van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL. 2008. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 3(4):e1927.
41. Waubant E, Gee L, Bacchetti P, Sloan R, Cotleur A, Rudick R, Goodkin D. 2001. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol 112(1-2):139-145.
42. Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, Leppert D. 2003. IFN-beta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesion in patients with SPMS. Neurology 60(1):52-57.
43. Weinstock-Guttman B, Bhasi K, Badgett D, Tamaño-Blanco M, Minhas M, Feichter J, Patrick K, Munschauer F, Bakshi R, Ramanathan M. 2008. Genomic effects of once-weekly, intramuscular interferon-b1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 205(1-2): 113-125.
44. Wiesemann E, Deb M, Trebst C, Hemmer B, Stangel M, Windhagen A. 2008. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferonbeta treatment in patients with multiple sclerosis. Mult Scler 14(2):166-176.